GLP-1-induced gastroparesis
What the FDA labels record as adverse events, each one tied back to the evidence it came from.
What is GLP-1-induced gastroparesis?
Gastric emptying delayed enough to cause persistent nausea, vomiting or food sitting undigested.
A 2023 JAMA case-control study (PMID 37335445) found a 3.7-fold increase in clinically diagnosed gastroparesis against bupropion-naltrexone. Risk climbs with higher doses, faster titration and pre-existing diabetic autonomic neuropathy; symptoms usually settle within four to eight weeks of reducing or stopping.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where GLP-1-induced gastroparesis comes up on this site
Connected terms
Other terms under Side effects
Where the evidence lives
- Side-effect timeline tool
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers